Compare L3Harris Technologies Inc (LHX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs BIO-TECHNE Corp — how do they compare? L3Harris Technologies Inc trades at $236.97 (market cap $44.12B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: L3Harris Technologies Inc is far larger — about 3.9× BIO-TECHNE Corp's market cap, and L3Harris Technologies Inc pays the higher dividend (2.11%). Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and BIO-TECHNE Corp for 64 Days on average.
| LHX | TECH | |
|---|---|---|
Market Cap | $44.12B | $11.36B |
Volume | 1,202,852 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $378.48 | $72.61 |
52-Week Low | $233.63 | $43.31 |
Typical Hold Time | 56 Days | 64 Days |
Enterprise Value | $54.56B | $11.39B |
Dividend Yield | 2.11% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $236.97, up 1.43% today, with a bearish technical signal despite strong fundamentals. The company reported revenue of $21.87B in 2025, with net income of $1.61B and improving profit margins. Recent contract wins, including a $6B THAAD propulsion deal with Lockheed Martin, highlight growth prospects. However, multiple law firm investigations into the company have emerged in September 2026, creating investor uncertainty.
The outlook is mixed: analyst consensus is bullish with a $340 price target, but technical indicators and legal overhangs pose risks. Earnings beats in recent quarters support fundamental strength, yet sentiment is tempered by bearish momentum and potential legal liabilities. Upside depends on contract execution and resolution of investigations.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
